학술논문
Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry
Document Type
Original Paper
Author
Isnardi, Carolina A.; Roberts, Karen; Saurit, Verónica; Petkovic, Ingrid; Báez, Roberto M.; Quintana, Rosana; Tissera, Yohana; Ornella, Sofía; D.Angelo Exeni, Maria Eugenia; Pisoni, Cecilia N.; Castro Coello, Vanessa V.; Berbotto, Guillermo; Haye Salinas, María J.; Velozo, Edson; Reyes Torres, Álvaro A.; Tanten, Romina; Zelaya, Marcos D.; Gobbi, Carla; Alonso, Carla G.; de los Ángeles Severina, María; Vivero, Florencia; Paula, Alba; Cogo, Adriana K.; Alle, Gelsomina; Pera, Mariana; Nieto, Romina E.; Cosatti, Micaela; Asnal, Cecilia; Pereira, Dora; Albiero, Juan A.; Savio, Verónica G.; Maldonado, Federico N.; Gamba, María Julieta; Germán, Noelia F.; Baños, Andrea; Gallino Yanzi, Josefina; Gálvez Elkin, María Soledad; Morbiducci, Julieta S.; Martire, María Victoria; Maldonado Ficco, Hernán; Schmid, Maria Marcela; Villafañe Torres, Jaime A.; de los Ángeles Correa, Maria; Medina, María Alejandra; Cusa, María Alejandra; Scafati, Julia; Agüero, Santiago E.; Lloves Schenone, Nicolás M.; Soriano, Enrique R.; Graf, Cesar; Pons-Estel, Bernardo A.; Gomez, Gimena; Landi, Margarita; De la Vega, María Celina; Pons-Estel, Guillermo J.
Source
Clinical Rheumatology: Journal of the International League of Associations for Rheumatology. 42(2):563-578
Subject
Language
English
ISSN
0770-3198
1434-9949
1434-9949
Abstract
Background/objective: This study aims to describe the course and to identify poor prognostic factors of SARS-CoV-2 infection in patients with rheumatic diseases.Methods: Patients ≥ 18 years of age, with a rheumatic disease, who had confirmed SARS-CoV-2 infection were consecutively included by major rheumatology centers from Argentina, in the national, observational SAR-COVID registry between August 13, 2020 and July 31, 2021. Hospitalization, oxygen requirement, and death were considered poor COVID-19 outcomes.Results: A total of 1915 patients were included. The most frequent rheumatic diseases were rheumatoid arthritis (42%) and systemic lupus erythematosus (16%). Comorbidities were reported in half of them (48%). Symptoms were reported by 95% of the patients, 28% were hospitalized, 8% were admitted to the intensive care unit (ICU), and 4% died due to COVID-19. During hospitalization, 9% required non-invasive mechanical ventilation (NIMV) or high flow oxygen devices and 17% invasive mechanical ventilation (IMV). In multivariate analysis models, using poor COVID-19 outcomes as dependent variables, older age, male gender, higher disease activity, treatment with glucocorticoids or rituximab, and the presence of at least one comorbidity and a greater number of them were associated with worse prognosis. In addition, patients with public health insurance and Mestizos were more likely to require hospitalization.Conclusions: In addition to the known poor prognostic factors, in this cohort of patients with rheumatic diseases, high disease activity, and treatment with glucocorticoids and rituximab were associated with worse COVID-19 outcomes. Furthermore, patients with public health insurance and Mestizos were 44% and 39% more likely to be hospitalized, respectively.Study registration: This study has been registered in ClinicalTrials.gov under the number NCT04568421.[Table Removed]